Differential degradation of calpastatin by μ‐ and m‐calpain in Ca2+‐enriched human neuroblastoma LAN‐5 cells
Open Access
- 9 June 2000
- journal article
- Published by Wiley in FEBS Letters
- Vol. 475 (1), 17-21
- https://doi.org/10.1016/s0014-5793(00)01613-6
Abstract
In neuroblastoma LAN‐5 cells during calpain activation, in addition to the two expressed 70 kDa and 30 kDa calpastatin forms, other inhibitory species are produced, having molecular masses of 50 kDa and 15 kDa. At longer times of incubation, both native and new calpastatin species disappear. The formation of these new calpastatins as well as the decrease in intracellular total calpastatin activity are mediated by calpain itself, as indicated by the effect of the synthetic calpain inhibitor I, which prevents both degradative processes. Analysis of the calcium concentrations required for the two processes indicates that the first conservative proteolytic event is mediated by μ‐calpain, whereas the second one is preferentially carried out by m‐calpain. The appearance of the 15 kDa form, containing only the calpastatin repetitive inhibitory domain and identified also in red cells of hypertensive rats as the major inhibitor form, can be considered a marker of intracellular calpain activation, and it can be used for the monitoring of the involvement of calpain in pathological situations.Keywords
This publication has 37 references indexed in Scilit:
- Studies on Calpain Expression during Differentiation of Rat Satellite Cells in Primary Cultures in the Presence of Heparin or a Mimic CompoundExperimental Cell Research, 1999
- Suppression of okadaic acid-induced apoptosis by overexpression of calpastatin in human UVr-1 cellsFEBS Letters, 1999
- Cleavage of the calpain inhibitor, calpastatin, during apoptosisCell Death & Differentiation, 1998
- Inhibition of the calpain-mediated proteolysis of protein kinase C enhances lytic activity in human NK cellsCellular Immunology, 1991
- The calpain-calpastatin system: structural and functional propertiesThe Journal of Nutritional Biochemistry, 1991
- The calpastatin defect in hypertension is possibly due to a specific degradation by calpainBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991
- Isovalerylcarnitine is a specific activator of the high calcium requiring calpain formsBiochemical and Biophysical Research Communications, 1990
- Characterization of the calpastatin defect in erythrocytes from patients with essential hypertensionBiochemical and Biophysical Research Communications, 1988
- Erythrocyte deficiency in calpain inhibitor activity in essential hypertension.Hypertension, 1988
- Cloning of mouse myeloma cells and detection of rare variantsJournal of Cellular Physiology, 1972